PriceTargets.com logo

NASDAQ:XENT - Intersect ENT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $27.96
  • Forecasted Upside: 4.33 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$26.80 As of 10/27/2021 01:00 AM ET
▼ -0.07 (-0.26%)

This chart shows the closing price for XENT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Intersect ENT Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XENT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XENT

Analyst Price Target is $27.96
▲ +4.33% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Intersect ENT in the last 3 months. The average price target is $27.96, with a high forecast of $32.00 and a low forecast of $23.00. The average price target represents a 4.33% upside from the last price of $26.80.

This chart shows the closing price for XENT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in Intersect ENT. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
5/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
8/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
11/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
1/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/11/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$28.25Low
8/10/2021BTIG ResearchDowngradeBuy ➝ NeutralLow
8/9/2021GuggenheimDowngradeBuy ➝ Neutral$28.30Low
8/6/2021Canaccord GenuityDowngradeBuy ➝ Hold$29.00 ➝ $28.25High
6/24/2021SVB LeerinkUpgradeMarket Perform ➝ Outperform$21.00 ➝ $23.00High
5/11/2021SVB LeerinkLower Price TargetMarket Perform$23.00 ➝ $21.00Low
3/10/2021SVB LeerinkBoost Price TargetMarket Perform$24.00 ➝ $25.00Medium
1/15/2021Piper SandlerBoost Price TargetNeutral$17.00 ➝ $23.00Medium
1/11/2021Canaccord GenuityUpgradeHold ➝ Buy$18.00 ➝ $25.00Low
12/3/2020SVB LeerinkBoost Price TargetMarket Perform$18.00 ➝ $22.00High
11/19/2020BTIG ResearchUpgradeNeutral ➝ Buy$32.00High
11/3/2020SVB LeerinkLower Price TargetMarket Perform$19.50 ➝ $18.00High
11/2/2020Piper SandlerBoost Price TargetIn-Line ➝ Neutral$16.00 ➝ $17.00Medium
10/22/2020Piper SandlerLower Price TargetNeutral$17.00 ➝ $16.00Medium
10/8/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$19.00High
8/7/2020GuggenheimUpgradeNeutral ➝ Buy$30.00High
8/5/2020SVB LeerinkBoost Price TargetMarket Perform$18.50 ➝ $19.50Medium
8/5/2020Canaccord GenuityReiterated RatingHold$18.00High
8/4/2020Piper SandlerBoost Price TargetNeutral$14.00 ➝ $17.00High
8/4/2020OppenheimerReiterated RatingHoldLow
7/15/2020SVB LeerinkBoost Price TargetMarket Perform$14.00 ➝ $18.50Low
6/29/2020SVB LeerinkLower Price TargetMarket Perform$15.00 ➝ $14.00High
6/23/2020OppenheimerInitiated CoverageMarket PerformHigh
6/10/2020BTIG ResearchReiterated RatingHoldHigh
5/12/2020SVB LeerinkBoost Price TargetMarket Perform$13.00 ➝ $15.00High
5/12/2020JPMorgan Chase & Co.Lower Price TargetOverweight$28.00 ➝ $18.00High
5/12/2020Piper SandlerLower Price TargetNeutral$23.00 ➝ $14.00Medium
5/12/2020Canaccord GenuityDowngradeBuy ➝ HoldHigh
4/15/2020Bank of AmericaDowngradeBuy ➝ Underperform$28.00 ➝ $10.00High
4/14/2020SVB LeerinkLower Price TargetMarket Perform$28.00 ➝ $13.00High
4/13/2020BTIG ResearchReiterated RatingHoldMedium
3/24/2020BTIG ResearchReiterated RatingHoldLow
2/25/2020Canaccord GenuityReiterated RatingBuy$30.00High
12/20/2019JPMorgan Chase & Co.Boost Price TargetOverweight$25.00 ➝ $28.00Medium
11/1/2019Piper Jaffray CompaniesSet Price TargetHold$21.00N/A
8/2/2019GuggenheimDowngradeBuy ➝ NeutralHigh
8/2/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$30.00 ➝ $17.00High
7/10/2019Northland SecuritiesUpgradeUnder Perform ➝ Market Perform$20.00Low
6/21/2019Berenberg BankDowngradeBuy ➝ Hold$35.00 ➝ $27.00High
5/7/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$41.00 ➝ $29.00High
5/7/2019Northland SecuritiesDowngradeMarket Perform ➝ Under Perform$28.00 ➝ $20.00High
2/26/2019BTIG ResearchReiterated RatingHoldHigh
2/26/2019Canaccord GenuityBoost Price TargetBuy ➝ Buy$36.00 ➝ $40.00Medium
11/5/2018Northland SecuritiesReiterated RatingHold$28.00High
10/17/2018Northland SecuritiesReiterated RatingHold$28.00Low
8/2/2018BTIG ResearchReiterated RatingHoldHigh
8/1/2018Canaccord GenuityReiterated RatingBuyHigh
8/1/2018Piper Jaffray CompaniesLower Price TargetOverweight$45.00 ➝ $40.00High
5/7/2018Canaccord GenuityReiterated RatingBuyLow
5/2/2018Northland SecuritiesReiterated RatingHold$32.00Low
5/2/2018BTIG ResearchReiterated RatingHoldLow
5/2/2018JPMorgan Chase & Co.Reiterated RatingOverweight$48.00Low
4/20/2018Berenberg BankInitiated CoverageBuyLow
3/1/2018GuggenheimReiterated RatingBuyLow
1/2/2018JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightHigh
12/15/2017GuggenheimReiterated RatingBuy$41.00Low
12/11/2017Canaccord GenuityReiterated RatingBuy$36.00Medium
11/7/2017BTIG ResearchReiterated RatingHoldN/A
11/3/2017Northland SecuritiesReiterated RatingHold$25.00N/A
9/13/2017Canaccord GenuityBoost Price TargetBuy$32.00 ➝ $37.00Low
9/11/2017Bank of AmericaBoost Price TargetBuy$33.00 ➝ $40.00High
8/22/2017Piper Jaffray CompaniesReiterated RatingBuy$35.00Low
8/2/2017Canaccord GenuityReiterated RatingBuy$32.00Medium
8/2/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$27.00 ➝ $31.00High
8/2/2017Northland SecuritiesReiterated RatingHold$25.00High
5/31/2017Northland SecuritiesDowngradeOutperform ➝ Market PerformMedium
5/10/2017William BlairReiterated RatingOutperformLow
5/4/2017Northland SecuritiesBoost Price TargetOutperform$17.00 ➝ $22.00High
5/3/2017Canaccord GenuityReiterated RatingBuyHigh
5/3/2017WedbushBoost Price TargetOutperform ➝ Outperform$25.00 ➝ $26.00High
3/13/2017Northland SecuritiesReiterated RatingBuy$17.00Low
3/8/2017Canaccord GenuityInitiated CoverageBuy$17.00Low
3/6/2017Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$15.00 ➝ $19.00N/A
2/24/2017WedbushReiterated RatingOutperform$25.00N/A
2/21/2017Canaccord GenuityReiterated RatingBuy$16.00N/A
1/23/2017Canaccord GenuitySet Price TargetBuy$16.00N/A
1/11/2017WedbushReiterated RatingOutperform$25.00N/A
12/6/2016GuggenheimInitiated CoverageBuy$20.00N/A
11/4/2016SVB LeerinkReiterated RatingOutperform$21.00 ➝ $14.00N/A
11/2/2016Canaccord GenuitySet Price TargetBuy$20.00N/A
11/2/2016JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$25.00 ➝ $16.00N/A
(Data available from 10/27/2016 forward)

News Sentiment Rating

0.46 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/31/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/30/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2021
  • 10 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2021

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Intersect ENT logo
Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. Its products include PROPEL and SINUVA. The PROPEL used to maintain the opening and locally deliver steroid after sinus surgery. The SINUVA is used to treat adult patients with ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.
Read More

Today's Range

Now: $26.80
Low: $26.66
High: $26.87

50 Day Range

MA: $27.34
Low: $27.06
High: $28.01

52 Week Range

Now: $26.80
Low: $14.68
High: $28.17

Volume

328,664 shs

Average Volume

402,329 shs

Market Capitalization

$895.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63

Frequently Asked Questions

What sell-side analysts currently cover shares of Intersect ENT?

The following Wall Street sell-side analysts have issued research reports on Intersect ENT in the last twelve months: BTIG Research, Canaccord Genuity, Guggenheim, Piper Sandler, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for XENT.

What is the current price target for Intersect ENT?

5 Wall Street analysts have set twelve-month price targets for Intersect ENT in the last year. Their average twelve-month price target is $27.96, suggesting a possible upside of 4.1%. BTIG Research has the highest price target set, predicting XENT will reach $32.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $23.00 for Intersect ENT in the next year.
View the latest price targets for XENT.

What is the current consensus analyst rating for Intersect ENT?

Intersect ENT currently has 5 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in XENT, but not buy more shares or sell existing shares.
View the latest ratings for XENT.

What other companies compete with Intersect ENT?

Other companies that are similar to Intersect ENT include AtriCure, The Beauty Health, Axonics, NuVasive, Silk Road Medical, iRhythm Technologies, Glaukos, Pulmonx, Inovio Pharmaceuticals, Cardiovascular Systems, Atrion, OrthoPediatrics, Sight Sciences, Treace Medical Concepts and LeMaitre Vascular.

How do I contact Intersect ENT's investor relations team?

Intersect ENT's physical mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider's listed phone number is (650) 641-2100 and its investor relations email address is [email protected] The official website for Intersect ENT is www.intersectent.com.